How investing in research and validation creates measurable business growth and differentiation.

Introduction – Research Is No Longer Optional

For much of the dietary supplement industry’s history, clinical research was viewed as a strategic luxury—valuable, but not essential. It was often reserved for larger companies with the resources to invest in long-term studies, while many brands relied on ingredient-level data or “borrowed science” to support product claims. Research was perceived as expensive, time-consuming and disconnected from immediate commercial return. That paradigm has fundamentally changed.

Today, research is no longer optional—it is expected, visible and increasingly scrutinized. Consumers are more informed and skeptical, regulators are tightening standards around substantiation, and retailers and practitioners are demanding stronger evidence before recommending products.1,2 At the same time, investors are evaluating scientific credibility as a core component of business value—not an afterthought.3

This shift is reflected in the rapid expansion of clinical research in the supplement industry. As previously highlighted, the number of dietary supplement clinical trials increased by more than 240 percent over the past decade, signaling a clear move toward evidence-based validation.1

Importantly, the barriers to entry have also fallen. Advances in artificial intelligence, decentralized clinical trial models, and specialized CRO ecosystems have made research faster, more accessible and more cost-efficient than ever before.

The result is a convergence of expectations across the entire value chain—consumers, regulators, retailers, practitioners and investors are aligned around one principle: proof matters.

Research is no longer a cost center—it is the price of entry.

And if research is now required, the more important question becomes: what is the return?

The Old Mindset: Research as a Cost Center

For many years, the prevailing view across the supplement and functional food industry was that clinical research represented a significant cost burden rather than a strategic investment. Clinical trials were often perceived as requiring substantial capital, extended timelines and uncertain outcomes—placing them out of reach for many companies and difficult to justify from a near-term financial perspective.

This perception fostered a series of limiting behaviors. Companies became hesitant to invest due to the fear of negative or inconclusive results, which could undermine product positioning or delay commercialization. Instead, many relied on “borrowed science”—leveraging published research on individual ingredients to support finished-product claims, even when formulations differed meaningfully from the original study conditions.1 At the organizational level, this reinforced a marketing-first mindset, where claims were developed ahead of robust validation, and scientific substantiation was often retrofitted to support existing narratives. Short-term ROI thinking further discouraged investment, as the benefits—brand trust, differentiation and long-term growth—were not always immediately quantifiable.

The result was widespread commoditization. Products with similar formulations competed on price, branding and distribution rather than proven efficacy. Without proprietary data or product-specific validation, meaningful differentiation became increasingly difficult.

That environment no longer exists. Regulatory expectations have tightened, consumer skepticism has increased, and stakeholders across the value chain are demanding stronger evidence.2

The cost-center mindset around research is no longer sustainable.

The New Reality: Lower Barriers, Higher Expectations

The economics and execution of clinical research have changed dramatically, creating a clear inflection point. What was once complex, slow, and cost-prohibitive is now becoming faster, more accessible, and strategically essential.

Contract research organizations (CROs) have evolved significantly. Decentralized and hybrid trial models now enable more efficient recruitment, broader population reach, and reduced operational costs. At the same time, artificial intelligence is streamlining study design, optimizing inclusion criteria, accelerating analysis, and improving the likelihood of successful outcomes.

Beyond traditional randomized controlled trials, real-world evidence (RWE) is emerging as a powerful complement—capturing how products perform across diverse populations in everyday conditions. Digital health tools, including wearables and mobile applications, are expanding the ability to track outcomes in real time.

Together, these advances have lowered the barriers to generating meaningful evidence while raising expectations across stakeholders. Regulators expect stronger substantiation, consumers demand proof, and retailers and practitioners prioritize evidence-backed products.4

The cost of not doing research is now greater than doing it.

The ROI Framework: How Research Creates Value

If research is now the price of entry, the more important question becomes: how does it create measurable business value?

Research is not a single outcome—it is a multi-dimensional return engine that compounds across the organization.

The 5 Pillars of Research ROI

1. Brand Equity & Trust

Evidence-backed products build trust. Consumers are more likely to purchase—and repurchase—products that deliver measurable results, leading to higher lifetime value and reduced churn. Over time, this trust lowers customer acquisition costs and strengthens brand loyalty.

2. Claim Strength & Differentiation

Robust research enables precise, defensible claims. Brands can move beyond generic structure/function language to more targeted, evidence-aligned messaging. This strengthens positioning with retailers and practitioners, who increasingly prioritize products with clear scientific backing.

3. Proprietary Advantage

Owning research on finished products creates a defensible competitive moat. Unlike “borrowed science,” proprietary clinical data reflects the actual formulation, dose and delivery system—making it difficult for competitors to replicate. This also supports layered intellectual property strategies built on data, not just composition.

4. Revenue Acceleration

When products are supported by strong evidence, adoption curves accelerate. A well-documented example is New Chapter’s Bone Strength product, which leveraged proprietary research to move from a crowded field of commodity calcium products to a leading market position within two years.1 Evidence drives confidence—and confidence drives sales.

5. Investor & Exit Value

Scientific validation is increasingly viewed as a proxy for business quality. Companies with strong research programs demonstrate lower regulatory risk, clearer differentiation, and stronger growth potential—factors that translate into higher valuation multiples and more attractive acquisition opportunities.5

Research does not deliver a single return—it compounds value across brand, product and enterprise levels simultaneously.

AI + Evidence = Exponential ROI

While clinical research has always created value, artificial intelligence is fundamentally changing the scale and speed at which that value is realized. AI is not simply making research more efficient—it is transforming it into a continuous, compounding asset.

One of AI’s most immediate impacts is reducing cost while increasing insight density. Machine learning models can analyze vast bodies of scientific literature, identify relevant endpoints, and optimize study design—allowing companies to generate more meaningful outcomes with fewer resources. This improves the efficiency of research investment and increases the likelihood that studies will yield actionable results.6

AI also enhances predictive modeling, enabling companies to identify optimal formulations, dosing strategies and target populations before clinical trials begin. By reducing uncertainty, this approach improves study success rates and minimizes the risk of inconclusive or underpowered outcomes.

Beyond individual studies, AI enables evidence aggregation across multiple data sources—including clinical trials, mechanistic research, and real-world evidence. This integrated view strengthens confidence in product performance and supports more precise, defensible claims.

Perhaps most importantly, AI shifts research from a one-time validation event to a continuous validation process. As new data is generated—through post-market feedback, digital health tools, and ongoing studies—AI systems can update and refine the evidence base in real time. This creates a dynamic feedback loop that continuously improves both product performance and scientific credibility.7

Frameworks such as NutriSelect’s NScore reflect this evolution, translating complex, multi-layered evidence into structured evaluations that can be updated as new data emerges.

Research is no longer a fixed investment—it becomes a living asset that grows in value over time.

From “Borrowed Science” to Owned Evidence

For years, much of the supplement industry has relied on what can be described as “borrowed science,” leveraging published research on individual ingredients to support finished-product claims. While this approach provided a foundation for early growth, it is increasingly misaligned with both scientific rigor and regulatory expectations.

At its core, the issue is straightforward: ingredient-level research does not equal product-level efficacy. Finished formulations introduce variables—dose, delivery format, ingredient interactions, and bioavailability—that can significantly alter outcomes. As a result, extrapolating claims from isolated ingredient studies to complex products introduces both scientific uncertainty and regulatory risk.

This gap becomes more pronounced as formulations grow more sophisticated. Multi-ingredient systems, personalized approaches, and condition-specific targeting all increase the importance of understanding how a product performs as a whole—not just how its individual components behave in isolation.

Brands that rely solely on supplier-provided data often lack control over their own scientific narrative. In contrast, companies that invest in owned evidence—through finished-product trials, real-world data, and mechanistic validation—gain a distinct advantage. They can make more precise claims, respond confidently to regulatory scrutiny, and differentiate in ways that competitors cannot easily replicate.

There is also a risk dimension. Over-reliance on borrowed science increases the likelihood of over-claiming, particularly when evidence is stretched beyond its original context.8 Owned data reduces this risk by aligning claims directly with product-specific outcomes.

The implication is clear: If you don’t own your science, you don’t own your differentiation.

Case Lens: What Winning Brands Are Doing Differently

A growing cohort of companies is demonstrating what it looks like to operationalize research as a strategic advantage. While their product categories may differ, their approach to evidence generation and utilization follows a consistent set of patterns.

First, leading brands are investing in finished-product clinical trials, ensuring that validation reflects the actual formulation, dosage, and delivery system brought to market. This shift from ingredient-level to product-level evidence enables more precise claims and reduces regulatory risk.

Second, they are publishing research in peer-reviewed journals, increasing transparency and strengthening credibility with practitioners, retailers, and increasingly informed consumers. Publication signals confidence in both methodology and outcomes.

Third, many are leveraging real-world evidence (RWE) dashboards, integrating data from consumer usage, digital health tools, and post-market feedback. This allows brands to monitor performance continuously and refine positioning based on real-world outcomes.

In parallel, leading companies are beginning to integrate AI into their substantiation strategies, using it to synthesize evidence, identify gaps, and enhance claim alignment. Just as importantly, they are aligning R&D and marketing early in the development process, ensuring that scientific validation and product positioning evolve together rather than sequentially.

The result of these combined practices is measurable. These brands tend to scale faster, command premium positioning, and build stronger, more durable trust with both consumers and professional channels.9 What differentiates them is not simply that they invest in research—but that they integrate it into how the business operates.

Strategic Shift: Research as a Growth Engine

As the role of research continues to evolve, the most important shift is not operational—it is strategic. Leading organizations are no longer treating research as a downstream function or validation step. Instead, they are integrating it into the core architecture of product development and brand strategy.

In this model, research informs every stage of the value chain. It guides formulation decisions, ensuring that products are built around evidence-based mechanisms and optimal dosing. It shapes claims development, enabling precise, defensible messaging aligned with real outcomes. It strengthens marketing, replacing broad narratives with proof-driven positioning. And it supports partnerships, from retailers to practitioners to investors, all of whom increasingly prioritize evidence-backed products.10

This integration shifts organizations from a reactive posture to a proactive one. Rather than retrofitting science to support existing products, companies design products with validation in mind from the outset—reducing risk, improving efficiency, and increasing the likelihood of commercial success.

Importantly, this approach aligns science, business, and brand into a unified strategy. Research is no longer siloed within R&D; it becomes a shared asset that informs decision-making across functions and throughout the product lifecycle.

The reframe is clear: Research is not what you do after building a product. It is how you build the product. Organizations that adopt this mindset will not only differentiate more effectively—they will build more resilient, scalable and credible businesses in an increasingly evidence-driven market.11

The Future: Continuous Validation & Intelligent Evidence

As the industry moves forward, the next evolution of research will be defined by continuity rather than completion. Traditional models treated validation as a finite milestone—an endpoint achieved through a single study or series of trials. In contrast, the emerging paradigm centers on continuous validation, where evidence evolves alongside product use, scientific discovery and consumer data.

This shift is closely tied to the rise of Intelligent Ingredients, which depend on ongoing data integration to refine their performance, mechanisms and relevance over time. Real-time feedback loops—enabled by digital health tools, real-world evidence, and post-market analytics—allow companies to monitor outcomes, identify trends, and adjust both formulation and positioning dynamically.

At the same time, advances in personalization are driving more individualized outcomes, where ingredient performance is understood in the context of specific populations, biological profiles and usage patterns. This further reinforces the need for adaptive, continuously updated evidence models.

AI plays a central role in this future by enabling credibility scoring and evidence synthesis at scale, transforming fragmented data into structured, actionable insight. These systems provide a foundation for more transparent, objective evaluation of product performance across the market.12

The implication is clear: research is no longer a discrete initiative. Research becomes infrastructure—embedded, ongoing and essential to how products are developed, validated and differentiated.

Conclusion—From Cost Center to Competitive Advantage

The nutrition industry has crossed a critical threshold. Research is no longer a differentiator reserved for a select few—it is expected, visible and measurable across the market. Consumers look for proof, regulators demand substantiation, retailers and practitioners prioritize credibility, and investors assess evidence as a proxy for long-term value.

In this environment, the question is no longer whether to invest in research, but how early and how strategically that investment is made. Companies that embrace research as a core capability—integrated, continuous, and aligned with product and brand strategy—will move faster, differentiate more clearly, and build more durable trust.

Those that delay will find themselves competing in a shrinking space defined by commoditization and skepticism. In the era of evidence-based nutrition, research is no longer the cost of doing business—it is the advantage that defines it. NIE

References:

1 Clark, W.D. (2024). Unlocking Success Through Clinical Research in Supplements.

2 Federal Trade Commission (2023). Health Products Compliance Guidance.

3 Deloitte Insights (2024). Evidence-Based Differentiation in Consumer Health Investment.

4 Krumholz, H.M. et al. (2021). Real-World Evidence and the Learning Health System. NEJM Catalyst.

5 McKinsey & Company (2024). The Role of Evidence and Differentiation in Consumer Health Growth.

6 Kourou, K. et al. (2023). Machine Learning in Nutrition Science. Trends in Food Science & Technology.

7 Esteva, A. et al. (2019). A Guide to Deep Learning in Healthcare. Nature Medicine.

8 U.S. Food & Drug Administration (2022–2024). Warning Letters Related to Dietary Supplement Claims.

9 Nutrition Business Journal (2024). Trends in Evidence-Based Differentiation and Premium Positioning in Supplements.

10 Deloitte Insights (2024). Integrating Science and Strategy in Consumer Health Innovation.

11 McKinsey & Company (2023). Building Evidence-Driven Growth Models in Health and Wellness.

12 National Institute of Standards and Technology (NIST) (2023). AI Risk Management Framework (AI RMF 1.0).

Bill Clark, PhD is the founder and CEO of NutriSelect.ai, an AI-powered platform redefining credibility in the dietary supplement and functional food industries. NutriSelect.ai integrates scientific validation, clinical evidence and advanced data analytics to bring transparency, trust and evidence-based decision-making to brands, practitioners, investors and consumers. A veteran scientist and industry executive with nearly 30 years of experience, Clark is a published author, sought-after speaker, and recognized thought leader at the intersection of nutrition science, artificial intelligence, and conscious leadership. He is also the founder and co-host of “The Bioactive Nexus,” a science-forward podcast exploring the research, regulation and innovation shaping bioactive ingredients and supplements. In parallel, he is the creator and host of “Beyond Limits – Where Spirit Meets Science,” a show examining human potential, leadership, and the convergence of science, spirituality, and personal transformation. He can be reached at [email protected], www.nutriselect.ai, www.natprologix.com, www.thebioactivenexus.com and www.drbillclark.life.